MedicinalProductIndication - FHIR Resource (r4)


This MedicinalProductIndication Resource uses the FHIR API standard for access and structure.

Validate an MedicinalProductIndication FHIR Resource (r4)



Resource Attributes

AttributeField is listTypeDescription
comorbiditytrueCodeableConcept# Comorbidity (concurrent condition) or co-infection as part of the indication
diseaseStatusfalseCodeableConcept# The status of the disease or symptom for which the indication applies
diseaseSymptomProcedurefalseCodeableConcept# The disease, symptom or procedure that is the indication for treatment
durationfalseQuantity# Timing or duration information as part of the indication
intendedEffectfalseCodeableConcept# The intended effect, aim or strategy to be achieved by the indication
otherTherapytrueData Type# Information about the use of the medicinal product in relation to other therapies described as part of the indication
populationtruePopulation# The population group to which this applies
subjecttrueReference# The medication for which this is an indication
undesirableEffecttrueReference# Describe the undesirable effects of the medicinal product

MedicinalProductIndication Example

{
  "resourceType": "MedicinalProductIndication",
  "id": "example",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>diseaseSymptomProcedure</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). <span>(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span></p><p><b>comorbidity</b>: Hipsurgery <span>(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span></p><p><b>intendedEffect</b>: PRYLX <span>(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span></p><p><b>population</b>: </p></div>"
  },
  "diseaseSymptomProcedure": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
        "code": "Venousthromboembolismprophylaxis"
      }
    ],
    "text": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."
  },
  "comorbidity": [
    {
      "coding": [
        {
          "system": "http://ema.europa.eu/example/comorbidity",
          "code": "Hipsurgery"
        }
      ]
    }
  ],
  "intendedEffect": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/intendedeffect",
        "code": "PRYLX"
      }
    ]
  },
  "population": [
    {
      "ageRange": {
        "low": {
          "value": 18,
          "unit": "a"
        }
      }
    }
  ]
}

MedicinalProductIndication Structure

{
  "resourceType" : "MedicinalProductIndication",
  // from Resource: id, meta, implicitRules, and language
  // from DomainResource: text, contained, extension, and modifierExtension
  "subject" : [{ Reference(MedicinalProduct|Medication) }], // The medication for which this is an indication
  "diseaseSymptomProcedure" : { CodeableConcept }, // The disease, symptom or procedure that is the indication for treatment
  "diseaseStatus" : { CodeableConcept }, // The status of the disease or symptom for which the indication applies
  "comorbidity" : [{ CodeableConcept }], // Comorbidity (concurrent condition) or co-infection as part of the indication
  "intendedEffect" : { CodeableConcept }, // The intended effect, aim or strategy to be achieved by the indication
  "duration" : { Quantity }, // Timing or duration information as part of the indication
  "otherTherapy" : [{ // Information about the use of the medicinal product in relation to other therapies described as part of the indication
    "therapyRelationshipType" : { CodeableConcept }, // R!  The type of relationship between the medicinal product indication or contraindication and another therapy
    // medication[x]: 
      Reference to a specific medication (active substance, medicinal product or class of products) as part of an indication or contraindication. One of these 2:
    "medicationCodeableConcept" : { CodeableConcept }
    "medicationReference" : { Reference(MedicinalProduct|Medication|Substance|
    SubstanceSpecification) }
  }],
  "undesirableEffect" : [{ Reference(MedicinalProductUndesirableEffect) }], // Describe the undesirable effects of the medicinal product
  "population" : [{ Population }] // The population group to which this applies
}

MedicinalProductIndication Search Parameters

The following search parameters can be used to query MedicinalProductIndication resources. Just submit them like so:

https://api.1up.health/fhir/r4/MedicinalProductIndication?query-param=queryvalue
Search ParameterField TypeResource Fields Searched
subjectreferencesubject